You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 124 No. 1, January 1988 TABLE OF CONTENTS
  Archives
  •  Online Features
  Vignettes
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (11)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Maternal Pemphigus Foliaceus With Cell Surface Antibody Bound in Neonatal Epidermis

Russell W. Eyre, MD; John R. Stanley, MD
Dermatology Branch National Cancer Institute Bldg 10, Room 12N-238 National Institutes of Health Bethesda, MD 20892

Arch Dermatol. 1988;124(1):25-27.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

There are two major types of pemphigus, pemphigus foliaceus (PF), in which blisters form due to acantholysis in the superficial epidermis, and pemphigus vulgaris (PV), in which acantholysis occurs in the deeper epidermis, just above the basal layer.1 Mucous membrane lesions, flaccid bullae, and extensive erosions are commonly seen in PV; whereas, in PF, superficial crusts and scales appear, often in a seborrheic distribution, and mucous membrane lesions or extensive erosions are rarely seen. Patients with each type of pemphigus have autoantibodies to different keratinocyte cell surface molecules.2,3 Patients with PF have antibodies to a characteristic complex of polypeptides of 260 000,160 000, 110000, and 85 000 molecular weight (mol wt), as detected by immunoprecipitation of human epidermal extracts.3 These polypeptides include desmoglein I, a 160 000-mol wt core desmosomal glycoprotein and, possibly, other desmosomal proteins. Patients with PV have antibodies to a different, characteristic complex of polypeptides of 210000, 130000, and . . . [Full Text PDF of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1988 American Medical Association. All Rights Reserved.